Pancreatic Cancer Research

ResearcherChiba UniversityActive in the last 2 years

Shigetsugu Takano

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6495-0422; OpenAlex author ID A5022239113, A5035413225. Sources: OpenAlex.

Their work

Papers
50 (first author 22, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
68
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: 2 papers · 2015: 2 papers · 2016: 6 papers · 2017: 6 papers · 2018: 2 papers · 2019: 3 papers · 2020: 4 papers · 2021: 7 papers · 2022: 3 papers · 2023: 4 papers · 2024: 4 papers · 2025: 3 papers · 2026: 2 papers

Papers 50

  1. Complement Factor B Blockade by Iptacopan Drives Antitumor Complement-Based Immunomodulation in Pancreatic Cancer Microenvironment. First author DOI 10.1016/j.ajpath.2026.08.005↗
  2. Prognostic Impact of Unplanned Hospitalization During First-Line Gemcitabine Plus Nab-Paclitaxel Therapy for Unresectable Pancreatic Cancer: A Single-Center Re… Co-author DOI 10.3390/cancers18020194↗
  3. Inhibition of C5a-C5aR1 axis suppresses tumour progression by enhancing antitumour immunity and chemotherapeutic effect in pancreatic ductal adenocarcinoma. First author DOI 10.1038/s41416-025-03185-0↗
  4. Serum fucosylated receptor expression-enhancing protein 5 as a biomarker for early stage pancreatic cancer. Co-author DOI 10.3892/ol.2025.15302↗
  5. [A Case of Long-Term Survival after Pulmonary Resection for Oligometastatic Pancreatic Cancer Following Chemotherapy]. Co-author PMID 41546200↗
  6. ECM1 and KRT6A are involved in tumor progression and chemoresistance in the effect of dexamethasone on pancreatic cancer. Co-author DOI 10.1111/cas.16175↗
  7. Preoperative Prediction of Long-Term Survival After Surgery in Patients with Resectable Pancreatic Ductal Adenocarcinoma. First author DOI 10.1245/s10434-024-15648-4↗
  8. ASO Author Reflections: Importance of Preoperative Prediction of Survival in Resectable Pancreatic Ductal Adenocarcinoma. First author DOI 10.1245/s10434-024-15853-1↗
  9. [Ⅳ. Recent Topics of Precision Medicine for Patients with Pancreatic Cancer]. Co-author PMID 39571982↗
  10. Clinical benefits of pulmonary resection for lung metastases from pancreatic cancer. First author DOI 10.1007/s00423-023-03198-4↗
  11. Complex glandular pattern is an aggressive morphology that predicts poor prognosis of pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.anndiagpath.2023.152110↗
  12. Semaphorin 3 C enhances putative cancer stemness and accelerates peritoneal dissemination in pancreatic cancer. First author DOI 10.1186/s12935-023-03008-3↗
  13. [Retrospective Study of Preoperative Serial Pancreatic Juice Aspiration Cytological Examination(SPACE)for Early Preoperative Detection of Pancreatic Cancer]. Co-author PMID 38303282↗
  14. The effect of the low stromal ratio induced by neoadjuvant chemotherapy on recurrence patterns in borderline resectable pancreatic ductal adenocarcinoma. First author DOI 10.1007/s10585-021-10142-7↗
  15. Prosaposin, tumor-secreted protein, promotes pancreatic cancer progression by decreasing tumor-infiltrating lymphocytes. First author DOI 10.1111/cas.15444↗
  16. [Ⅰ. Recent Trends in Chemotherapy followed by Surgery for Patients with Locally Advanced Biliary-Pancreatic Cancer]. Co-author PMID 36281595↗
  17. Complement factor B regulates cellular senescence and is associated with poor prognosis in pancreatic cancer. First author DOI 10.1007/s13402-021-00614-z↗
  18. Analysis of circulating cell-free DNA after endoscopic ultrasound-guided fine needle aspiration in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2021.04.001↗
  19. PTHrP Drives Pancreatic Cancer Growth and Metastasis and Reveals a New Therapeutic Vulnerability. Co-author DOI 10.1158/2159-8290.cd-20-1098↗
  20. Simultaneous brain and lung metastases of pancreatic ductal adenocarcinoma after curative pancreatectomy: a case report and literature review. First author DOI 10.1186/s12876-020-01587-3↗
  21. C4b-binding protein α-chain enhances antitumor immunity by facilitating the accumulation of tumor-infiltrating lymphocytes in the tumor microenvironment in pan… First author DOI 10.1186/s13046-021-02019-0↗
  22. Fucosylated C4b-binding protein α-chain, a novel serum biomarker that predicts lymph node metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2020.12388↗
  23. [Ⅲ.Surgical Treatment for Recurrence of Pancreatic Cancer]. Co-author PMID 34657053↗
  24. Comparing prognostic factors of Glut-1 expression and maximum standardized uptake value by FDG-PET in patients with resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.07.407↗
  25. Diverse transitions in diabetes status during the clinical course of patients with resectable pancreatic cancer. Co-author DOI 10.1093/jjco/hyaa136↗
  26. Needle tract seeding recurrence of pancreatic cancer in the gastric wall with paragastric lymph node metastasis after endoscopic ultrasound-guided fine needle … First author DOI 10.1186/s12876-020-1159-x↗
  27. [Ⅱ.Carbon Ion Radiation Therapy as Perioperative Treatment for Pancreatic Cancer]. Co-author PMID 33130735↗
  28. Conversion surgery for initially unresectable pancreatic cancer: current status and unresolved issues. First author DOI 10.1007/s00595-019-01804-x↗
  29. Is hepatic artery coil embolization useful in distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic cancer? Co-author DOI 10.1186/s12957-019-1667-8↗
  30. Successful treatment of a locally advanced unresectable pancreatic cancer patient with interstitial pneumonitis by conversion surgery following gemcitabine plu… First author DOI 10.3892/mco.2019.1807↗
  31. Expression of annexin II and stromal tenascin C promotes epithelial to mesenchymal transition and correlates with distant metastasis in pancreatic cancer. First author DOI 10.3892/ijmm.2018.3652↗
  32. Conversion surgery with gemcitabine plus nab-paclitaxel for locally advanced unresectable pancreatic cancer: A case report. First author DOI 10.3892/mco.2018.1688↗
  33. Grainyhead-like 2 (GRHL2) regulates epithelial plasticity in pancreatic cancer progression. First author DOI 10.1002/cam4.1212↗
  34. Combined hepatic arterial resection in pancreatic resections for locally advanced pancreatic cancer. Co-author DOI 10.1007/s00423-017-1578-5↗
  35. Sex Determining Region Y Box 9 Induces Chemoresistance in Pancreatic Cancer Cells by Induction of Putative Cancer Stem Cell Characteristics and Its High Expres… Co-author DOI 10.1097/mpa.0000000000000945↗
  36. Immune-complex level of cofilin-1 in sera is associated with cancer progression and poor prognosis in pancreatic cancer. First author DOI 10.1111/cas.13181↗
  37. Metadherin promotes metastasis by supporting putative cancer stem cell properties and epithelial plasticity in pancreatic cancer. First author DOI 10.18632/oncotarget.19802↗
  38. [IV. Distal Pancreatectomy with Celiac Axis Resection(DP-CAR)for Locally Advanced Pancreatic Cancer with Celiac Artery Invasion]. Co-author PMID 29066679↗
  39. Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags. First author DOI 10.1038/bjc.2016.295↗
  40. ETS-Transcription Factor ETV1 Regulates Stromal Expansion and Metastasis in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2016.06.005↗
  41. Low Stromal Area and High Stromal Microvessel Density Predict Poor Prognosis in Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000499↗
  42. Prrx1 isoform switching regulates pancreatic cancer invasion and metastatic colonization. Co-author DOI 10.1101/gad.263327.115↗
  43. [Two Cases of Remnant Pancreatic Cancer Treated Using Remnant Pancreatectomy Combined with Hepatic Arterial Resection]. Co-author PMID 28133092↗
  44. [A Case of Early-Onset Rapidly Progressive Cerebral Infarction with Trousseau's Syndrome in a Patient with Pancreatic Cancer Undergoing Surgery]. Co-author PMID 28133197↗
  45. [III. Repeat pancreatectomy for recurrent pancreatic cancer]. Co-author PMID 26665417↗
  46. [A Case of R0 Resection of Locally Advanced Pancreatic Cancer Following Chemoradiation Therapy]. Co-author PMID 26805371↗
  47. Tips and tricks of surgical technique for pancreatic cancer: portal vein resection and reconstruction (with videos). Co-author DOI 10.1002/jhbp.128↗
  48. [Liver, pancreas, biliary tract cancer. III. Pancreatectomy with Vascular Resection for Locally Advanced Pancreatic Cancer]. Co-author PMID 25528776↗
  49. Akt/mTOR signaling pathway is crucial for gemcitabine resistance induced by Annexin II in pancreatic cancer cells. First author DOI 10.1016/j.jss.2012.05.065↗
  50. The application of a three-step proteome analysis for identification of new biomarkers of pancreatic cancer. Co-author DOI 10.1155/2011/628787↗

Closest collaborators

The 25 strongest of 68 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masayuki Ohtsuka · 41 shared papers, 2012–2026 · strength 5.28
  2. Katsunori Furukawa · 26 shared papers, 2012–2022 · strength 2.14
  3. Hideyuki Yoshitomi · 27 shared papers, 2011–2021 · strength 1.91
  4. Masaru Miyazaki · 24 shared papers, 2011–2022 · strength 1.60
  5. Takanori Konishi · 8 shared papers, 2021–2025 · strength 1.59
  6. Shingo Kagawa · 20 shared papers, 2012–2021 · strength 1.35
  7. Hitoe Nishino · 8 shared papers, 2017–2025 · strength 1.25
  8. Kazuyuki Sogawa · 8 shared papers, 2011–2026 · strength 1.10
  9. Kensuke Suzuki · 6 shared papers, 2017–2025 · strength 0.90
  10. Yoji Miyahara · 6 shared papers, 2015–2022 · strength 0.67
  11. Masayuki Otsuka · 4 shared papers, 2017–2025 · strength 0.57
  12. Satoshi Tomizawa · 3 shared papers, 2021–2023 · strength 0.52
  13. Yusuke Kouchi · 3 shared papers, 2021–2024 · strength 0.50
  14. Takashi Kishimoto · 3 shared papers, 2021–2024 · strength 0.50
  15. Ryotaro Eto · 2 shared papers, 2023–2025 · strength 0.49
  16. Jun Kato · 3 shared papers, 2020–2026 · strength 0.43
  17. Fumio Nomura · 6 shared papers, 2011–2021 · strength 0.39
  18. Yoshiki Shinomiya · 2 shared papers, 2023–2024 · strength 0.39
  19. Kosuke Sasaki · 3 shared papers, 2021 · strength 0.37
  20. Rintaro Mikata · 4 shared papers, 2016–2021 · strength 0.35
  21. Motoyasu Kan · 2 shared papers, 2021–2026 · strength 0.33
  22. Hiroshi Ohyama · 2 shared papers, 2021–2026 · strength 0.33
  23. Daren Zhou · 1 shared paper, 2026 · strength 0.32
  24. Naoya Kato · 3 shared papers, 2020–2021 · strength 0.30
  25. Takeshi Tomonaga · 2 shared papers, 2011–2025 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.